A
Anna Bergamaschi
Researcher at University of Illinois at Urbana–Champaign
Publications - 34
Citations - 2941
Anna Bergamaschi is an academic researcher from University of Illinois at Urbana–Champaign. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 21, co-authored 27 publications receiving 2725 citations. Previous affiliations of Anna Bergamaschi include Rikshospitalet–Radiumhospitalet & Oslo University Hospital.
Papers
More filters
Journal ArticleDOI
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer
Anna Bergamaschi,Young Ho Kim,Pei Wang,Pei Wang,Therese Sørlie,Tina Hernandez-Boussard,Per Eystein Lønning,Robert Tibshirani,Anne Lise Børresen-Dale,Jonathan R. Pollack +9 more
TL;DR: A genome‐wide array‐based comparative genomic hybridization (array CGH) survey of CNAs in 89 breast tumors from a patient cohort with locally advanced disease links distinct cytoband loci harboring CNAs to specific clinicopathological parameters, including tumor grade, estrogen receptor status, presence of TP53 mutation, and overall survival.
Journal ArticleDOI
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome
Anna Bergamaschi,Elda Tagliabue,Therese Sørlie,Therese Sørlie,Bjørn Naume,Tiziana Triulzi,Rosaria Orlandi,Hege G. Russnes,J. M. Nesland,Raija Tammi,Päivi Auvinen,Veli-Matti Kosma,Sylvie Ménard,Anne Lise Børresen-Dale,Anne Lise Børresen-Dale +14 more
TL;DR: It is suggested that primary breast tumours can be classified on the basis of the expression of extracellular matrix (ECM) composition and that this classification provides relevant information on the biology of breast carcinomas, further supporting the hypothesis that clinical outcome is strongly related to stromal characteristics.
Journal ArticleDOI
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
Ana Bosch,Zhiqiang Li,Anna Bergamaschi,Haley Ellis,Eneda Toska,Aleix Prat,Jessica J. Tao,Daniel E. Spratt,Nerissa Viola-Villegas,Pau Castel,Gerard Minuesa,Natasha Morse,Jordi Rodon,Yasir H. Ibrahim,Javier Cortes,Jose Perez-Garcia,Patricia Galván,Judit Grueso,Marta Guzman,John A. Katzenellenbogen,Michaelz Kharas,Jason S. Lewis,Maura N. Dickler,Violeta Serra,Neal Rosen,Sarat Chandarlapaty,Sarat Chandarlapaty,Maurizio Scaltriti,José Baselga,José Baselga +29 more
TL;DR: It is proposed that increased ER transcriptional activity may be a reactive mechanism that limits the activity of PI3K inhibitors and that combinedPI3K and ER inhibition is a rational approach to target these tumors.
Posted Content
Regularized Multivariate Regression for Identifying Master Predictors with Application to Integrative Genomics Study of Breast Cancer
TL;DR: The proposed method remMap - REgularized Multivariate regression for identifying MAster Predictors - for fitting multivariate response regression models under the high-dimension-low-sample-size setting is applied to a breast cancer study, in which genome wide RNA transcript levels and DNA copy numbers were measured for 172 tumor samples.
Journal ArticleDOI
Regularized Multivariate Regression for Identifying Master Predictors with Application to Integrative Genomics Study of Breast Cancer
TL;DR: In this article, the authors proposed a new method remMap -regularized multivariate regression for identifying MAster Predictors -for fitting multivariate response regression models under the high-dimension-low-sample-size setting.